The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Adjuvant denosumab for breast cancer: What efficacy in the D-CARE trial will translate into cost effectiveness?
Nathan William Dana Lamond
No relevant relationships to disclose
Chris Skedgel
No relevant relationships to disclose
Daniel Rayson
No relevant relationships to disclose
Tallal Younis
No relevant relationships to disclose